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ABSTRACT 
 
Introduction: Appearance concerns are common in systemic sclerosis (SSc), but no 
study has examined their association with sex or race/ethnicity.  
Methods: SSc patients were from the Scleroderma Patient-centered Intervention 
Network Cohort. Presence or absence of appearance concerns was assessed with a 
single item. Multivariate logistic regression was used to assess factors associated with 
appearance concerns, including sex, race/ethnicity, and pre-specified 
sociodemographic and disease covariates.  
Results: Of 644 patients, appearance concerns were present in 72%, including 421 of 
565 women (75%) and 42 of 79 men (53%), as well as 392 of 550 patients who 
identified as White (71%), 35 of 41 identified as Black (85%), and 36 of 53 identified as 
another race/ethnicity (68%). In multivariate analysis, women had significantly greater 
odds of reporting appearance concerns than men (odds ratio (OR) = 2.97, 95% 
confidence interval (CI) = 1.78-4.96, p < .001) than men. Black patients had significantly 
greater odds of appearance concerns than White patients in unadjusted (OR = 2.64, 
95% CI = 1.01-6.34, p = .030), but not multivariate analysis (OR = 1.71, 95% CI = 0.65-
4.48, p = .279). Older patients were less likely (OR = 0.98 per year, 95% CI = 0.96-0.99, 
p = .009) and patients with moderate hand contractures were more likely to report 
appearance concerns (OR = 1.97, 95% CI=1.12-3.46, p=.019).  
Conclusion: Women are substantially more likely than men to have appearance 
concerns. Black patients are more likely than White patients, but this may be due to 
more severe changes in appearance. 
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INTRODUCTION 
Disfiguring appearance changes are common in systemic sclerosis (SSc) 
andinclude telangiectasias, changes to the texture of the skin, hand contractures, skin 
pigmentation changes, and altered facial features (2). These visible differences are 
unique to the disease and distinct from appearance changes in other medical 
conditions. Furthermore, appearance changes in SSc commonly affect body parts that 
are highly visible and play a central role in social interactions, such as the face, mouth, 
and hands (1,3). Treatments can lessen the impact of some SSc symptoms, but do not 
alleviate manifestations of irreversible tissue damage that affect appearance.  
Concerns about appearance are common among people with acquired 
disfigurements from medical illness or injury (4). In SSc, visual manifestations of the 
disease are associated with greater body image dissatisfaction and social discomfort 
and poorer overall psychosocial functioning (5-8). SSc patients with more severe 
disease symptoms, such as more significant skin changes in the hands, report higher 
levels of body image dissatisfaction, lower appearance self-esteem, and greater 
symptoms of depression and anxiety (7-9). Severity of facial disfigurement in SSc, 
based on observer ratings, has similarly been associated with higher levels of general 
distress, worry, and feelings of being more noticeable to others (10,11). Compared to 
older patients, younger people with SSc experience greater social discomfort in relation 
to their appearance (6, 9). No published studies, however, have investigated the degree 
to which sex and race/ethnicity may be associated with appearance concerns in SSc. 
Among other groups of people with visible differences, women experience more 
worry about their appearance and greater general distress, social anxiety, and social 
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avoidance than men (12-15). Women with visible appearance differences are more 
likely than men to have multiple appearance concerns and tend to experience the 
impact of their disfigurements on social interactions differently (14). For instance, 
women are more likely to express embarrassment, self-consciousness, and worry about 
their visible differences, whereas men may be more inclined to experience feelings of 
aggression and hostility (14,16). Overall, women are more likely to have difficulty 
adjusting to visible differences than men (13, 15, 17). 
Less is known about the association of race/ethnicity with appearance concerns 
and body image. One survey of 458 adults with visible disfigurements found that people 
with non-White racial/ethnic backgrounds experienced significantly greater worry about 
their appearance and greater concern that their condition was noticeable to others than 
White respondents (18). One possible reason for this is that visible disfigurements may 
disproportionately affect non-White individuals. People with darker skin colors are more 
vulnerable to visible differences due to changes in skin pigmentation compared to 
individuals with lighter skin tones, and the psychosocial burden of pigmentation changes 
is greater for individuals with darker skin types (19). In SSc, skin involvement and 
pigmentation changes are more common among Black patients than White patients, 
although White patients are more likely to have telangiectasias (20).  
The objective of the present study was to examine the association of sex and 
race/ethnicity with the presence of appearance concerns in a large, international cohort 
of SSc patients. We hypothesized that female SSc patients would be more likely to have 
appearance concerns than males and that Black SSc patients would be more likely to 
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report appearance concerns than White patients, controlling for other sociodemographic 
and disease variables. 
METHODS 
Patients and Procedure 
The sample consisted of patients enrolled in the Scleroderma Patient-centered 
Intervention Network (SPIN) Cohort (21) who completed baseline study questionnaires 
from January 2014 through August 2015. Patients were enrolled at 21 SPIN centers 
from Canada, the USA, and the UK. To be eligible for the SPIN Cohort, patients must 
have a confirmed diagnosis of SSc according to 2013 American College of 
Rheumatology/European League Against Rheumatism classification criteria (22), be ≥ 
18 years of age, have the ability to give informed consent, be fluent in English or 
French, and have access and the ability to respond to questionnaires via the Internet. 
The SPIN sample is a convenience sample. Eligible patients are invited by attending 
physicians or supervised nurse coordinators from SPIN centers to participate in the 
SPIN Cohort, and written informed consent is obtained. The local SPIN physician or 
nurse coordinator completes a medical data form that is submitted online to initiate 
patient registration. After completion of online registration, an automated welcoming 
email is sent to participants with instructions for activating their SPIN account and 
completing SPIN Cohort measures online. SPIN Cohort patients complete outcome 
measures via the Internet upon enrollment and subsequently every three months. 
Patients who had complete data at their baseline assessment for all variables 
necessary for planned multivariate analyses were included in the present study. The 
SPIN Cohort study was approved by the Research Ethics Committee of the Jewish 
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General Hospital, Montréal, Canada and by the research ethics committees of each 
participating center. 
Measures 
Sociodemographic Characteristics. Patients enrolled in the SPIN Cohort provided 
sociodemographic data, including age, sex, race/ethnicity, education level, marital 
status, and employment status. Response options for race/ethnicity differed slightly for 
patients from Canada, the USA, and the UK samples, consistent with how racial/ethnic 
status is typically characterized in each country. In the Canadian sample, patients could 
identify as White, Black, Aboriginal, Asian, Latin American, or Arab. In the USA sample, 
patients could identify as White (non-Hispanic), African American, Hispanic or Latino, 
Asian, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, or 
Mixed-race. In the UK sample, patients could identify as White, African, or Asian. In the 
present study, racial/ethnic status was narrowed to three categories across Canadian, 
American, and UK samples, consisting of White, Black, or Other. Across countries, 
responses indicating White racial/ethnic status were combined to create one White 
race/ethnicity category; responses indicating Black, African American, or African were 
combined to create one Black race/ethnicity category; and other responses were 
combined to create one Other race/ethnicity category. 
Disease-related Characteristics. SPIN physicians or nurse coordinators provided 
disease information, including time since onset of the first non-Raynaud’s phenomenon 
symptom (i.e., disease duration), disease subtype (limited or diffuse SSc), 
telangiectasias, skin pigmentation changes, hand contractures, and skin thickening on 
both hands. Limited SSc was defined as skin involvement distal to the elbows and 
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knees only, whereas diffuse SSc was defined as skin involvement proximal to the 
elbows and knees, and/or the trunk (23). Telangiectasias were defined as the visible 
dilation of superficial cutaneous blood vessels that collapse upon pressure and fill 
slowly when pressure is released, excluding normal sun exposure-related 
telangiectasias (24). In the present study, telangiectasias were coded as present on the 
body and face, present on the body only, or none. Skin pigmentation changes included 
either hyper- or hypo-pigmentation of the skin. As with telangiectasias, skin 
pigmentation changes were coded as present on the body and face, present on the 
body only, or none. Hand contractures, which entail limitations in the range of motion of 
a joint, secondary to tightening around the joint, were measured for small joints on the 
hands (i.e., proximal interphalangeal joints, metacarpals, and/or wrists) and categorized 
as None/Mild (0-25% limitation in range of motion), Moderate (25-50%), or Severe 
(>50%). Skin thickening of the fingers was defined as skin thickening or hardening 
extending proximal to the metacarpophalangeal joints (21). 
Presence of Appearance Concerns. The Derriford Appearance Scale (DAS-24) 
(25,26) is a self-report measure of distress related to problems with appearance and 
assesses the degree of dysfunction experienced by people living with such body image 
disturbance, including social anxiety and avoidance related to self-consciousness. The 
DAS-24 includes an introductory item, which is not scored as part of the scale, that 
asks, “Is there any aspect of your appearance (however small) that concerns you at 
all?” (yes/no). This item was used as the primary outcome in the present study.  
Data Analysis 
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Descriptive statistics were calculated for all sociodemographic and disease 
variables, including means and standard deviations for continuous variables. Chi-square 
tests were used for categorical variables, and a one-way ANOVA was used for 
continuous variables to compare patients on sociodemographic and disease 
characteristics across sex and race/ethnicity categories. For variables with statistically 
significant overall tests, Bonferroni-corrected comparisons were done to assess 
statistical significance between pairs of race/ethnicity groups. To maintain the family-
wise error rate < .05, the Bonferroni-corrected α for each of the three subgroup 
comparisons for each variable was .0167. 
The associations of sociodemographic variables (age, sex, race/ethnicity, marital 
status, education level), and disease variables (telangiectasis, skin pigmentation 
changes, hand contractures, skin thickening of fingers, disease subtype) were assessed 
using binary logistic regression. All variables included in the regression analysis were 
selected a priori. Discrimination and calibration of the multivariate model were assessed 
with the c-index and Hosmer-Lemeshow goodness-of-fit test statistic, respectively (27). 
The c-index is the percentage of comparisons where patients with appearance concerns 
had a higher predicted probability of having appearance concerns than patients without 
appearance concerns for all possible pairs where patients were discrepant on outcome 
variable status. The Hosmer-Lemeshow goodness-of-fit statistic is a measure of the 
accuracy of the predicted number of cases of appearance concerns compared to the 
number of patients who actually reported appearance concerns across the spectrum of 
probabilities. A relatively large p value indicates reasonably good model fit (27). All 
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analyses were conducted using SPSS (Version 22), and statistical tests were two-sided 
with alpha < .05.  
RESULTS 
Sample Characteristics  
In total, 757 SSc patients completed baseline assessments, of which 717 
answered the appearance concern item, including 644 with data for all variables 
included in the logistic regression analysis. Of these, 463 (72%) indicated that there was 
an aspect of their appearance that caused them concern. 
Sociodemographic and disease characteristics are displayed in Table 1. Average 
age in the total sample was 55.3 years (Standard Deviation [SD] = 12.1), and the 
majority of patients were White (N = 550, 85%) and married or living as married (N = 
471, 73%). Mean time since onset of the first non-Raynaud’s symptom was 11.5 (SD = 
8.7) years. 
The sample included 41 (6%) Black patients and 53 (8%) patients who identified 
as a member of one of the other racial/ethnic groups. As shown in Table 1, White 
patients were older and more likely to be married than Black patients, but less likely to 
have skin thickening on the hands and have diffuse SSc (statistically significant, p < 
.0167). There were also statistically significant differences between White and Black 
patients in presence of telangiectasias and skin pigmentation changes. White patients 
were older and less likely to have diffuse SSc than patients from other racial/ethnic 
groups (statistically significant, p < .0167). There were also statistically significant 
differences in skin pigmentation changes. (see Table 1). 
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There were a total of 565 (88%) women and 79 (12%) men in the total sample. 
There were no statistically significant differences between women and men for any 
sociodemographic or disease variables (see Table 1). 
Appearance Concerns 
Among women, 75% (521 of 565) reported appearance concerns, compared to 
53% (42 of 79) of men (p < .001). Across racial/ethnic groups, 85% (35 of 41) of Black 
patients reported appearance concerns, compared to 71% (392 of 550) of White 
patients and 68% (36 of 53) from other racial/ethnic groups (p = .122). 
As shown in Table 2, on an unadjusted basis, the odds of appearance concerns 
were greater for female patients compared to male patients (OR = 2.70, 95% 
Confidence Interval [CI] = 1.73-4.22, p < .001), and for Black patients versus White 
patients (OR = 2.64, 95% CI = 1.01-6.34, p = .030). Patients with other racial/ethnic 
status did not have significantly different odds compared to White patients (OR = 0.92, 
95% CI = 0.52-1.65, p = .788). Other variables that were significantly associated with 
the presence of appearance concerns on an unadjusted basis included age, disease 
subtype, hand contractures, and skin thickening of the fingers.  
In the multivariate analysis, only sex, age, and presence of moderate hand 
contractures were significantly associated with appearance concerns. The odds of 
appearance concerns for female SSc patients were significantly greater than for males 
(OR = 2.97, 95% CI = 1.78-4.96, p < .001). Older patients were also less likely to report 
appearance concerns than younger patients (OR = 0.98 per year, 95% CI = 0.96-0.99, p 
= .009), equivalent to a reduction of 18% in the OR for every 10-year increase in age. 
Race/ethnicity was not statistically significant, although the odds of reporting 
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appearance concerns among Black patients were greater than for White patients (OR = 
1.71, 95% CI = 0.65-4.48, p = .279). The odds of reporting appearance concerns for 
patients with moderate hand contractures were almost twice those of patients with no or 
only mild hand contractures (OR = 1.97, 95% CI = 1.12-3.46, p = .019) (see Table 2). 
Model fit for the 11 predictors included was less than ideal based on the Hosmer-
Lemeshow test (2(8, N = 644) = 17.44, p = .026), and the c-index statistic was 0.67. 
DISCUSSION  
The main finding was that women with SSc were substantially more likely than 
men to report appearance concerns, controlling for sociodemographic and disease 
variables. Black racial/ethnic group membership was significantly associated with 
appearance concerns at the bivariate level; however, the association was not 
statistically significant after accounting for the influences of other sociodemographic and 
disease variables. Older age was significantly associated with reduced odds of 
appearance concerns, and moderate hand contractures were significantly associated 
with greater odds.  
The finding that female SSc patients had greater odds of experiencing appearance 
concerns is consistent with previous research on sex and visible differences, which has 
highlighted that women tend to experience greater distress, social anxiety, worry, self-
consciousness, and difficulty adjusting to disfiguring appearance changes than men 
(12-15). The finding that younger patients had greater odds of experiencing appearance 
concerns also aligns with previous research in SSc, which has reported greater social 
discomfort based on appearance among younger patients (6).  
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Although 85% of Black patients reported appearance concerns compared to 71% 
of White patients, race/ethnicity was not independently associated with appearance 
concerns in multivariate analysis. It is possible that the small number of Black people in 
the study could explain the non-significant result. This finding may also have occurred 
because Black patients tended to be younger, have diffuse disease, and have greater 
pigmentation changes and skin thickening on the fingers compared to White patients. 
The only other variable that was significantly associated with appearance concerns at 
the multivariate level was the presence of moderate hand contractures. This finding 
aligns with previous research demonstrating that hand contractures are linked to more 
dissatisfaction with appearance in SSc (5). The greater odds of having appearance 
concerns among individuals with moderate hand contractures compared to those with 
severe hand contractures is likely due to the small number of patients who had severe 
hand contractures and not because moderate hand contractures are more likely to 
create appearance concerns than more severe hand contractures.  
The present study is the first to specifically examine the presence of appearance 
concerns across sex and racial/ethnic groups in SSc, as well as other key 
sociodemographic and disease characteristics. Results highlight that multiple factors 
may contribute to appearance concerns in SSc. Overall, almost three of every four 
patients experience appearance concerns, and no single variable clearly separates 
patients with and without appearance concerns. For patients with appearance concerns, 
cognitive behavioural therapy (CBT) (4) and social skills training programs (28, 29) have 
been recommended as strategies to reduce social avoidance and increase self-esteem 
in social settings for other patient groups. Changing Faces, a UK not-for-profit 
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organization (www.changingfaces.org.uk), is an organization that has published a range 
of educational and self-help resources related to body image concerns due to visible 
differences that may also be relevant to SSc patients.  
The present study has limitations that should be considered in interpreting results. 
First, the SPIN Cohort constitutes a convenience sample of SSc patients receiving 
treatment at a SPIN recruiting center, and patients at these centers may differ from 
those in other settings. Additionally, SSc patients in the SPIN Cohort complete 
questionnaires online, which may further limit the generalizability of findings. An 
additional limitation of the present study relates to the nature of disease characteristics 
included in the analyses. Specifically, the majority of the variables included in the 
models consisted of fairly crude indicators of either the presence or absence of a 
particular disease factor and did not provide a measure of severity. This may have 
reduced the ability to identify any associations, if present, between the severity of visible 
differences from the disease and the presence of appearance concerns. An additional 
limitation is that the sample sizes of Black patients and those self-identified as members 
of another racial/ethnic group were small, which may have limited the ability to detect 
meaningful differences in the odds of reporting appearance concerns for these groups. 
These limitations may have been reflected in the model fit statistics, which suggested 
that the overall model fit was less than ideal (27). It is also possible that the relatively 
limited information obtained from the predictive model could have been due to the 
dichotomous outcome variable. Most patients reported the presence of appearance 
concerns, and measuring appearance concerns may not be something that is easily 
categorized as present or absent.  
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In sum, female SSc patients had significantly higher odds of appearance 
concerns than male patients, as did younger SSc patients compared to older individuals 
and those with moderate hand contractures compared to those with no/mild hand 
involvement. Although Black SSc patients had higher odds of experiencing appearance 
concerns than White patients on an unadjusted basis, this result was not statistically 
significant when accounting for the influence of other sociodemographic and disease 
characteristics. It may be the case that greater appearance concerns among Black 
patients reflect more significant appearance changes. Replications of the current study 
with larger samples of Black and other racial/ethnic groups are needed. In addition, 
future studies should include assessment of appearance concerns with a continuously 
measured outcome variable. 
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Table 1. Sociodemographic and Disease Characteristics (N = 644)  




Variable N = 644 
White 
 
N = 550 
Black 
 
N = 41 
Other 
 















Age (years),  
mean ± SD 
 
55.3 ± 12.1 56.5 ± 11.5a,b 47.7 ± 11.5a 48.1 ± 14.1b <.001 55.1 ± 12.0 56.2 ± 12.8 .462 
Education >12 years,  
n (%) 
 
512 (79.5) 434 (78.9) 33 (80.5) 45 (84.9) .579 451 (79.8) 61 (77.2) .591 
Currently employed  
(full or part-time), n 
(%) 
 
268 (41.7)c 225 (41.0)d 21 (51.2) 22 (41.5) .439 236 (41.8) 32 (41.0)e .901 
Married/living as 
married, n (%)  
 
471 (73.1) 413 (75.1)a 21 (51.2)a 37 (69.8) .003 412 (72.9) 59 (74.7) .741 
Time since onset of 
first non Raynaud’s 
symptoms (years), 
mean ± SD  
 
11.5 ± 8.7f 11.6 ± 8.9g 8.9 ± 5.6h 10.2 ± 7.8i .067 11.7 ± 8.8j 10.4 ± (7.8)k .227 
Patients with diffuse 
SSc, n (%) 
 
258 (40.1) 200 (36.4)a,b 28 (68.3)a 30 (56.6)b <.001 226 (40.0) 32 (40.5) .971 
Telangiectasias     <.001   .058 
None,  
n (%) 
183 (28.4) 137 (24.9)a 26 (63.4)a 20 (37.7)  153 (27.1) 30 (38.0)  
  26 
SD = standard deviation; aWhite patients statistically significantly different from Black patients; bWhite patients 
statistically significantly different from patients from another racial/ethnic group; cN = 643; dN = 549; eN = 78; fN = 595; 
gN = 510; hN = 40; iN = 45; jN = 519; kN = 76.
Body and face,  
n (%) 
298 (46.3) 273 (49.6)a 7 (17.1)a 18 (34.0)  262 (46.4) 36 (45.6)  
Body only,  
n (%) 
 
163 (25.3) 140 (25.5)a 8 (19.5)a 15 (28.3)  150 (26.5) 13 (16.5)  
Pigmentation 
changes 
    <.001   .497 
None,  
n (%) 
438 (68.0) 396 (72.0)a,b 13 (31.7)a 29 (54.7)b  385 (68.1) 53 (67.1)  
Body and face,  
n (%) 
105 (16.3) 71 (12.9)a,b 18 (43.9)a 16 (30.2)b  89 (15.8)  16 (20.3)  
Body only,  
n (%) 
 
101 (15.7) 83 (15.1)a,b 10 (24.4)a 8 (15.1)b  
91 (16.1) 10 (12.7)  
Hand contractures     .898   .988 
No/mild (0-25%),  
n (%) 




121 (18.8) 102 (18.5) 7 (17.1) 12 (22.6)  106 (18.8) 15 (19.0)  
Severe (>50%),  
n (%) 
 
35 (5.4) 30 (5.5) 3 (7.3) 2 (3.8)  31 (5.5) 4 (5.1)  
Skin thickening of 
fingers, n (%) 
 
360 (55.9) 293 (53.3)a 31 (75.6)a 36 (67.9) .004 311 (55.0) 49 (62.0) .242 
Presence of 
appearance 
concerns, n (%) 
463 (71.9) 392 (71.3) 35 (85.4) 36 (67.9) .122 421 (74.5) 42 (53.2) <.001 
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Table 2. Unadjusted and Adjusted Comparisons of Appearance Concerns across Sociodemographic and Disease 
Variables  
 
Variable Unadjusted  




OR (95% CI)a 
 
p value 










Other 0.92 (0.52-1.65) .788 0.57 (0.30-1.11) .098 
Age 0.97 (0.96-0.98) <.001 0.98 (0.96-0.99) .009 
Female sex 2.70 (1.73-4.22) <.001 2.97 (1.78-4.96) <.001 
Education 12 years 0.69 (0.47-1.02) .063 0.74 (0.48-1.15) .179 
Not married/living as married  1.36 (0.92-2.00) .121 1.05 (0.68-1.61) .825 
Diffuse disease subtype  1.76 (1.24-2.50) .002 1.18 (0.76-1.83) .456 
Telangiectasias (reference = none)     
Body and face 0.81 (0.54-1.22) .313 1.51 (0.90-2.53) .120 
Body only 0.70 (0.44-1.09) .116 1.21 (0.78-1.88) .390 
Pigmentation changes  
(reference = none) 
    
  28 
Body and face 1.58 (0.96-2.58) .071 0.91 (0.53-1.59) .745 
Body only 1.50 (0.92-2.47) .108 1.01 (0.50-2.03) .976 
Hand contractures (reference = 
none) 
    
Moderate 2.33 (1.41-3.86) .001 1.97 (1.12-3.46) .019 
Severe 2.03 (0.88-4.70) .099 1.74 (0.66-4.59) .261 
Skin thickening on hands 1.64 (1.18-2.28) .003 1.40 (0.92-2.11) .114 
OR = Odds ratio; CI = Confidence interval; aAdjusted for age, sex, race/ethnicity, education level, marital status, 
disease subtype, telangiectasis, pigmentation changes, hand contractures, and skin thickening on fingers. 
 
